About the Association

The journal is the official publication of Translational Medicine Committee (www.wrsatm.com), Physician Society of Western Returned Scholars Association. With the aim of promoting the development of translational medicine in China, the Translational Medicine Committee spreads new concepts and technologies in translational medicine, promotes healthcare delivery, medical education and training, and community service, and bridges the gap between medical research and clinical practice.

About the Journal

Cancer Translational Medicine is a peer-reviewed online journal with Quarterly print on demand compilation of issues published. The journal is the official publication of Translational Medicine Committee, Physician Society of Western Returned Scholars Association. The journal’s full text is available online at https://plascipub.com/journal/cancer-translational-medicine. It allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.

Abstracting and Indexing Information

The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TDNet, Wanfang Data

The journal is indexed with, or included in, the following:
DOAJ

Journal Ethics

The Cancer Translational Medicine Journal and the Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely with the industry associations, such as the Committee on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc.,

Open Access Publication and Creative Commons Licensing

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Ahead of Print policy

Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. PlaSciPub will not make changes after publication of an article without following accepted procedures for making corrections to the scientific record.

Advertisements

While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:

• "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
• The Editorial Board has full and final approval over the content of all advertisements.
• Advertisers will never be shown any manuscripts or other content prior to publication.

Scope of the journal

The journal covers innovative basic, clinical and translational cancer research studies that bridge the laboratory and the clinic. Cancer Translational Medicine is especially interested in cancer risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and experimental therapeutics in the field of chemotherapy, radiotherapy and biotherapy (immune-therapy, gene-therapy, target-therapy, stem-cell-therapy and so on). Examples of content include:

• Translational, clinical, preventative, and epidemiologic cancer research
• Molecular and cellular level researches that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression
• New molecular mechanisms and interactions that support cancer phenotypes
• An incisive rationale that could interest a broad audience
• A generalizable conclusion with potentially broad impact

Potential Audience: Researchers focus on basic and translational cancer study, physician scientists, students, funding agencies, business developers